Drug intelligence / Profile preview

Quadrivalent Influenza Split Virus Vaccine

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular Injection

Overview

The quadrivalent influenza split virus vaccine is an inactivated vaccine designed to protect against four different strains of the influenza virus, including two A strains and two B strains. It is produced by propagating the viruses in embryonated chicken eggs, followed by harvesting, purification, and inactivation. The vaccine is formulated to contain 15 µg of hemagglutinin (HA) per strain in a 0.5 mL dose. It is administered via intramuscular injection.

Brand names: FLUARIX QUADRIVALENTFLUZONE QUADRIVALENT
Other names: 四价流感病毒裂解疫苗

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on Quadrivalent Influenza Split Virus Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quadrivalent Influenza Split Virus Vaccine.

Explore the full profile